This study carried out statistics and analysis on the immune function and prognosis of early-stage breast cancer patients with low HER-2 expression undergoing different chemotherapy combination and compared the differences in clinical efficacy, adverse reactions, and immune function of patients before and after chemotherapy. Here, ERBB2 is linked to breast cancer.